Genexine Inc. | Mutual Funds
Mutual Funds that own Genexine Inc.
Vanguard Total International Stock Index Fund
177,729
0.87%
0
0.01%
07/31/2018
iShares Core MSCI Emerging Markets ETF
127,349
0.62%
0
0.02%
09/05/2018
Vanguard Developed Markets Index Fund
69,211
0.34%
0
0.01%
07/31/2018
Baillie Gifford Overseas Growth Fund - Pacific Fund
48,964
0.24%
0
0.85%
04/30/2018
Government Pension Fund - Global (The)
45,766
0.22%
-43,870
0%
12/31/2017
Pacific Horizon Investment Trust Plc
44,392
0.22%
0
1.55%
10/31/2017
Mirae Asset TIGER Health Care ETF
31,292
0.15%
7,982
1.89%
04/30/2018
Vanguard FTSE All World (ex-US) Small Cap
29,950
0.15%
0
0.04%
07/31/2018
iShares Plc - Core MSCI Emerging Markets IMI UCITS ETF
22,891
0.11%
0
0.02%
09/05/2018
RAM (Lux) Systematic Funds - Emerging Markets Equities
17,128
0.08%
17,128
0.06%
06/30/2017
| Address |
4/F, Korea Bio Park Bldg. B
Seongnam-si GY 13488
Korea, Republic Of
|
|
Employees
|
- |
| Website |
http://www.genexine.com |
| Updated |
09/14/2018 |
| Genexine, Inc. engages in research and development of therapeutic vaccines hybrid Fc fusion proteins (hyFc) and DNA (deoxyribonucleic acid) therapeutic vaccines. It operates through the following business divisions: Novel drug development and Cell culture media manufacturing. The company was founded by Young Chul Sung on June 8, 1999 and is headquartered in Seongnam, South Korea. |
